risperidone (Perseris)

General information

• Class: Long-acting injectable antipsychotic
• Common US brands: PERSERIS
• Typical dose range: Establish oral tolerability before initiating depot therapy when feasible. Perseris is administered as a monthly subcutaneous injection.
• Long-acting injectable formulation available.
• Therapeutic drug monitoring not routinely recommended.
• Last reviewed: 2025-12-30

Dosing & forms

• Forms/strengths: Subcutaneous long-acting depot injection, administered monthly (q4wk). Product-specific preparation and injection technique apply.
• Frequency: Establish oral tolerability before initiating depot therapy when feasible. Perseris is administered as a monthly subcutaneous injection.
• Typical range: Establish oral tolerability before initiating depot therapy when feasible. Perseris is administered as a monthly subcutaneous injection.

Mechanism (brief)

Monthly subcutaneous long-acting risperidone depot (D2/5-HT2A antagonist) intended for schizophrenia maintenance when scheduled injection visits support adherence.

Metabolism & Half‑life

• Metabolism: CYP2D6
• Half‑life: Single-dose range 216–264 h

Therapeutic Drug Monitoring (TDM)

Recommended: No

Long‑acting injectable (LAI)

Monitoring highlights

• Weight/BMI and waist circumference; fasting lipids and glucose/HbA1c at baseline and periodically.
• Movement disorder monitoring (akathisia, parkinsonism, tardive dyskinesia), especially after initiation and dose adjustments.
• Prolactin-related symptom review (sexual dysfunction, menstrual changes, galactorrhea).
• Injection site assessment and documentation (site rotation, local reactions).

Sources

• PERSERIS (risperidone) extended-release injectable suspension — Prescribing Information — DailyMed (2025)
• RISPERDAL (risperidone) prescribing information — DailyMed (2025)
• The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia — American Psychiatric Association (2020)
• Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis — The Lancet (2013)
• AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsycharmacology — Pharmacopsychiatry (2018)